Atrial Fibrillation and Injected Aripiprazole: A Case Report

Innovations in Clinical Neuroscience

Adrian Baranchuk¹  Julie N. Ha²  Ross J. Baldessarini³  Anthi Stefatos⁴ 

[1] Dr. Baldessarini is with the Department of Psychiatry at Harvard Medical School in Boston, Massachusetts, and the International Consortium for Mood Psychotic Disorder Research at McLean Hospital in Belmont, Massachusetts.;Dr. Baranchuk is with the Department of Medicine at Queens University in Kingston, Ontario, Canada.;Dr. Vzquez is with the Department of Psychiatry at Queens University in Kingston, Ontario, Canada, and the International Consortium for Mood Psychotic Disorder Research at McLean Hospital in Belmont, Massachusetts.;Drs. Stefatos and Ha are with the Department of Psychiatry at Queens University in Kingston, Ontario, Canada.

关键词: Aripiprazole;    atrial fibrillation;    adverse effects;    schizoaffective disorder;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Background: Aripiprazole is a widely clinically employed antipsychotic drug for a range of indications. It has unusual pharmacodynamics as a dopamine D2 receptor partial-agonist with complex interactions with serotonin receptors and, a relatively unusual long elimination half-life. Although other atypical antipsychotics have been associated with an increased risk of atrial fibrillation, aripiprazole is considered to be relatively neutral in regard to its cardiac risk. We report a case of a 45-year-old Caucasian patient with schizoaffective disorder who developed acute atrial fibrillation (AF) several days after an intramuscular injection of a large long-acting dose of the drug after low oral doses had been well-tolerated. The patient responded to intravenous metoprolol and amiodarone and converted back to normal sinus rhythm within 24 hours, after having his oral aripiprazole dose lowered. The timing and dose-dependent effect of aripiprazole administration suggests an association between aripiprazole and the new onset of AF in this case, which calls for added clinical vigilance in patients with risk factors for stroke and in younger patients who could have predisposing factors for arrhythmias.

【 授权许可】

Unknown